Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

230 Views

Poster Session: Antimicrobial Novel Agents

1690 - Assessing the safety of TP-102 bacteriophage treatment in the management of diabetic foot infections

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

Ran Nir-Paz, MD

Infectious Diseases consultant
Hadassah-Hebrew University Medical Center
Jerusalem, Yerushalayim, Israel

Co-Author(s)

HO

Hadil Onallah, PhD

Hadassah-Hebrew University Medical Center
Jerusalem, Yerushalayim, Israel
YG

Yechiel N. Gellman, n/a

1Hadassah-Hebrew University Medical Center
Jerusalem, Yerushalayim, Israel
AH

Amir Haze, n/a

1Hadassah-Hebrew University Medical Center
Jerusalem, Yerushalayim, Israel
RB

Ron Braunstein, n/a

Hebrew University of Jerusalem
Jerusalem, Yerushalayim, Israel
RH

Ronen Hazan, PhD

Prof.
The Hebrew University
Jerusalem, Yerushalayim, Israel
CL

Clara Leandro, PhD

Technophage, Investigação e Desenvolvimento em Biotecnologia S.A.
Lisbon, Lisboa, Portugal
RB

Raquel Barbosa, PhD

Technophage, Investigação e Desenvolvimento em Biotecnologia S.A.
Lisbon, Lisboa, Portugal
HD

Helena Dordio, PhD

Technophage, Investigação e Desenvolvimento em Biotecnologia S.A.
Lisbon, Lisboa, Portugal
AW

Alexandra Wagner, PhD

Technophage, Investigação e Desenvolvimento em Biotecnologia S.A.
Lisbon, Lisboa, Portugal
SC

Sofia V. Corte Real, PhD

Scientific Advisor
Technophage, Investigação e Desenvolvimento em Biotecnologia S.A.
Lisbon, Lisboa, Portugal
MG

Miguel Garcia, n/a

Technophage, Investigação e Desenvolvimento em Biotecnologia S.A.
Lisbon, Lisboa, Portugal